31.05.2012

Miracor granted several U.S. patents

Miracor Medical Systems GmbH announced today that it has been granted three new U.S. patents covering a unique dual balloon method and the new “Wien Algorithm” of its novel PICSO system that ensures a stable and repeatable treatment designed to improve myocardial perfusion following primary angioplasty.

The Miracor PICSO Impulse System, which is CE-marked, is designed to treat acute heart attack STEMI patients following a coronary angioplasty. ‘STEMI’ is an acronym meaning ST-segment Elevation Myocardial Infarction. Heart attacks are divided into three types, according to their severity. A STEMI is the most severe type. In a STEMI, the coronary artery is completely blocked off by the blood clot, and as a result virtually all the heart muscle being supplied by the affected artery starts to die.

“Even after a successful coronary angioplasty, deficient myocardial reperfusion still manifests in about one in three STEMI patients, and this unsatisfactory incidence is strongly linked to unfavorable results for patients,” said Jon H. Hoem, Miracor CEO. “PICSO is designed to considerably amplify the redistribution of blood into the blood-starved myocardium of severe heart attack patients post-PCI,” added Hoem. “Of course, we are extremely pleased that our system now has a much stronger patent protection in the United States.”

Subscribe Newsletter


Stay up2date!

Get the startupticker.ch App
for your Phone or your Tablet!
   

Start-ups meet customers

Jürg Mausch is an old hand at the sales business. Today, he helps young companies find buyers. He reveals his tricks in our interview.

The Editorial Team

 

Partners

Sponsors